As basic cancer researchers, we design and analyze new compounds for their potential to be used as an alternative to classical chemotherapeutics.
Thereby, we assist in the development of novel cancer drugs that are highly effective and ideally cause fewer side effects.
Many chemotherapeutic agents still do not act solely on tumor leukemia cells. Therefore, they cause unpleasant side effects for patients. For this reason, we are interested in the identification of selective antitumoural or antileukemic compounds and, hence, the further development of non-platinum metal complexes (such as salen and salophen iron complexes, gold complexes, etc.). Additionally, we undertake investigations to identify new mechanisms of action.
